Status: Recruiting

Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid Malignancies

To find a recommended dose of PRAME-TCR-NK cells that can be given to patients with AML or MDS.

Participants needed: 44

Trial details

Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Jun 12, 2026Locations: 1

Eligibility criteria

18- 80 years of age. English and non-English speaking patients are eligible. [+21]

Positive beta HCG in female of child-bearing potential defined as not postmenopa... [+27]